ΔNp63-restricted viral mimicry response impedes cancer cell viability and remodels tumor microenvironment in esophageal squamous cell carcinoma
Valen Zhuoyou YuiD, Shan Shan SoiD, Bryan Chee-chad Lung, George Zhaozheng Hou, Carissa Wing-Yan WongiD, Larry Ka-Yue ChowiD, Michael King Yung ChungiD, Yhi WongiD, Claudia Lai-yin Wong, Desmond Kwan‐Kit Chan, Fion Siu‐Yin ChaniD, B. T.-t. Law, Kaiyan Xu, Zack Zhen Tan, Ka On LamiD, Anthony W.I. LoiD, Alfred King-yin LamiD, Dora Lai‐Wan KwongiD, Josephine Mun Yee KoiD, Wei DaiiD, Simon Ying-Kit LawiD, Maria Li LungiD
Abstract
Tumor protein p63 isoform {Delta}Np63 plays roles in the squamous epithelium and squamous cell carcinomas (SCCs), including esophageal SCC (ESCC). By integrating data from cell lines and our latest patient-derived organoid cultures, derived xenograft models, and clinical sample transcriptomic analyses, we identified a novel and robust oncogenic role of {Delta}Np63 in ESCC. We showed that {Delta}Np63 maintains the repression of cancer cell endogenous retrotransposon expression and cellular double-stranded RNA sensing. These subsequently lead to a restricted cancer cell viral mimicry response and suppressed induction of tumor-suppressive type I interferon (IFN-I) signaling through the regulations of Signal transducer and activator of transcription 1, Interferon regulatory factor 1, and cGAS-STING pathway. The cancer cell {Delta}Np63-IFN-I signaling axis affects both the cancer cell and tumor-infiltrating immune cell (TIIC) compartments. In cancer cells, depletion of {Delta}Np63 resulted in reduced cell viability. {Delta}Np63 expression is negatively associated with the anticancer responses to viral mimicry booster treatments targeting cancer cells. In the tumor microenvironment, cancer cell TP63 expression negatively correlates with multiple TIIC signatures in ESCC clinical samples. {Delta}Np63 depletion leads to increased cancer cell antigen presentation molecule expression and enhanced recruitment and reprogramming of tumor-infiltrating myeloid cells. Similar IFN-I signaling and TIIC signature association with {Delta}Np63 were also observed in lung SCC. These results support the potential application of {Delta}Np63 as a therapeutic target and a biomarker to guide candidate anticancer treatments exploring viral mimicry responses.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 14
- FWCI
- 1.95
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The USP28-{triangleup}Np63 axis is a vulnerability of squamous tumours
C. Prieto-Garcia, O. Hartmann, … M. E. Diefenbacher·bioRxiv·Jun 27, 2019
- CDK4/6 Inhibition Uncovers Subtype-Specific Vulnerabilities and Immune-Related Responses in Esophageal Squamous Cell Carcinoma.
Fabiana Moresi, Diego Japón-Ruiz, … Xavier Bisteau·Cell Death and DiseasePeer-reviewed·May 29, 2026
- Integrative multi-omic analysis identifies tumor-intrinsic p38 as a driver of immune exclusion in human epithelial cancers
Rebekah Dadey, Krishna Beer Singh, … Riyue Bao·bioRxiv·Jun 16, 2026
- Tumor-stromal IL1β/ NFκB / ESE3 Signal Axis Drives Pancreatic Cancer Fibrosis, Chemoresistance, Prognosis
- Overexpression of Interleukin-8 and Interleukin-13 as potent immune markers associated with survival and dietary habits in esophageal squamous cell carcinoma.
J. Talukdar, A. Malik, … S. Medhi·bioRxiv·Oct 17, 2022
- IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF-κB signaling pathway